Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have an option to purchase up to an additional 1,500,000 ADSs. BioNTech is listed on the Nasdaq Global Select Market under the symbol “BNTX.”
Headquartered in Germany, BioNTech is a biotechnology company that focuses on developing cancer treatments that are individualized for each patient. BioNTech combines research in immunology, cutting-edge therapeutic platforms and a suite of patient profiling and bioinformatic tools to develop individualized immunotherapies for cancer as well as other diseases, addressing the unique molecular signature of each patient’s underlying disease.
The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Yoojin L. Kim and Meaghan Kennedy. Partner Pritesh P. Shah and associates Tilak Koilvaram and Jennifer Leather provided intellectual property and technology advice. The tax team included partner David H. Schnabel and associate Summer Xia. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices.